In this interview, Jun Yang explains the science of discovery in pharmacogenomics before his presentation at ASHG 2019 (15-19 October 2019; Houston, TX, USA). He discusses the challenges of translation and clinical implementation, as well how he hopes the field will develop moving forward.
About the author:
Jung Yang is a faculty member at St. Jude Children’s Research Hospital, where he focuses on patient to patient variability in anticancer treatment responses. His work primarily focuses on the pharmacogenomics of leukemia treatment resistances and how genomics can give insight into anti-leukemia drug sensitivity and resistance. He has authored a number of papers on germline genetic mutations, racial and ethnic disparities and how gene variants generate susceptibility to cancer and to treatment failure.
Video originally published on BioTechniques, a digital platform from the Future Science Group providing the latest methods, techniques and protocols in life science.